gnrh receptor การใช้

GnRH receptor agonists, such as leuprolide and goserelin, were subsequently developed and used to treat prostate cancer.
No activating mutations of the GnRH receptor in humans have been described in the medical literature, and only one of the FSH receptor has been described, which presented as asymptomatic.
Initial interaction of any GnRH agonist, such as buserelin, with the GnRH receptor induces release of follicle-stimulating hormone ( FSH ) and luteinizing hormone ( LH ) by gonadotrophes.
Long-term exposure to constant levels of buserelin, rather than endogenous pulses, leads to downregulation of the GnRH receptors and subsequent suppression of the pituitary release of LH and FSH.
Its proposed mechanism of action is the desensitization of pituitary GnRH receptors leading to a decrease in gonadotropin release, and ovarian hormone serum concentrations similar to those achieved in postmenopausal women . it decreases pituitary secretion of the gonadotropins luteinizing hormone ( LH ) and follicle stimulating hormone ( FSH ).